Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Wellmarker Bio
R-Pharm
Icahn School of Medicine at Mount Sinai
Kuwait Cancer Control Center
Kineta Inc.
Fondazione del Piemonte per l'Oncologia
University of California, San Diego
Nanfang Hospital, Southern Medical University
City Clinical Oncology Hospital No 1
Silverback Therapeutics
Martin-Luther-Universität Halle-Wittenberg
ChineseAMS
ChineseAMS